Meeting News CoverageVideo

VIDEO: Managing HIV in special populations

SAN DIEGO — Anandi Sheth, MD, assistant professor of medicine at Emory University School of Medicine, summarizes four presentations from IDWeek 2015 that focused on HIV management in special populations.

Sheth mentions the WAVES study, which showed an improvement in viral outcomes among women who were treated with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences) vs. Norvir (ritonavir, AbbVie; RTV)-boosted Reyataz (atazanavir, Bristol-Myers Squibb) plus FTC/TDF. She also discusses HIV management among older adults, adolescents, substance users and those with psychiatric illnesses. 

Disclosures: Sheth reports no relevant financial disclosures.

SAN DIEGO — Anandi Sheth, MD, assistant professor of medicine at Emory University School of Medicine, summarizes four presentations from IDWeek 2015 that focused on HIV management in special populations.

Sheth mentions the WAVES study, which showed an improvement in viral outcomes among women who were treated with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences) vs. Norvir (ritonavir, AbbVie; RTV)-boosted Reyataz (atazanavir, Bristol-Myers Squibb) plus FTC/TDF. She also discusses HIV management among older adults, adolescents, substance users and those with psychiatric illnesses. 

Disclosures: Sheth reports no relevant financial disclosures.

    See more from IDWeek 2015